Grimes & Company Inc. Acquires 16,434 Shares of GSK plc (NYSE:GSK)

Grimes & Company Inc. lifted its holdings in GSK plc (NYSE:GSK - Free Report) by 11.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 156,309 shares of the pharmaceutical company's stock after purchasing an additional 16,434 shares during the quarter. Grimes & Company Inc.'s holdings in GSK were worth $6,055,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in GSK. Sierra Ocean LLC bought a new stake in shares of GSK in the fourth quarter worth $32,000. Parkside Financial Bank & Trust increased its holdings in GSK by 470.1% during the fourth quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock worth $34,000 after buying an additional 818 shares during the last quarter. Lee Danner & Bass Inc. acquired a new position in GSK during the fourth quarter worth $39,000. Bank Julius Baer & Co. Ltd Zurich acquired a new position in GSK during the fourth quarter worth $40,000. Finally, Atala Financial Inc acquired a new position in GSK during the fourth quarter worth $45,000. Institutional investors own 15.74% of the company's stock.

GSK Price Performance

NYSE:GSK opened at $40.50 on Tuesday. GSK plc has a one year low of $31.72 and a one year high of $44.67. The company has a market cap of $83.00 billion, a P/E ratio of 25.47, a P/E/G ratio of 1.12 and a beta of 0.52. The firm's fifty day moving average price is $38.22 and its two-hundred day moving average price is $36.73. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, beating the consensus estimate of $1.08 by $0.05. GSK had a net margin of 8.13% and a return on equity of 48.59%. The business had revenue of $10.06 billion for the quarter, compared to the consensus estimate of $7.52 billion. During the same period in the prior year, the company posted $0.43 earnings per share. GSK's revenue was up 2.1% compared to the same quarter last year. Equities analysts expect that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be given a dividend of $0.4216 per share. This is a boost from GSK's previous quarterly dividend of $0.39. The ex-dividend date is Friday, May 16th. This represents a $1.69 annualized dividend and a yield of 4.16%. GSK's dividend payout ratio is currently 86.60%.

Wall Street Analyst Weigh In

GSK has been the topic of a number of recent analyst reports. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a report on Monday, April 28th. Wall Street Zen downgraded shares of GSK from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Berenberg Bank restated a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Finally, BNP Paribas initiated coverage on shares of GSK in a report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 target price on the stock. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.